Tag: union

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Transaction in Own Shares

VANCOUVER and TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- SEIU Local 2 has now filed two unfair labour practice complaints against Dexterra Group, one in British Columbia and the other in Ontario, raising critical questions about whether public agencies should continue its relationship with the cleaning contractor.

MONTRÉAL, June 26, 2026 (GLOBE NEWSWIRE) -- Rogers Sugar Inc. (the “Company” or “Rogers Sugar”) (TSX: RSI) today announced that the ‘’United Food and Commercial Workers Union’’ representing the employees at its Taber sugar beet refinery has ratified the extension of its current collective agreement to March 2032.

MONTRÉAL, June 26, 2026 (GLOBE NEWSWIRE) -- Rogers Sugar Inc. (the “Company” or “Rogers Sugar”) (TSX: RSI) today announced that the ‘’United Food and Commercial Workers Union’’ representing the employees at its Taber sugar beet refinery has ratified the extension of its current collective agreement to March 2032.

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000^® Index, the large-cap Russell 1000^® Index, the small-to-mid-cap Russell 2500^® Index, and the Russell Midcap^® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4